isirv

About Guides FAQs

Font Size

SCREEN

Profile

Direction

Menu Style

Apply Reset  
In Brief
  1. ISIRV Journal: IRV Journal impact factor is now 4.4
  2. Abstract submission deadline for RSV2025 has been extended to 15 November.
13th International RSV Symposium (RSV2025)

Return to Menu

Immunological Assays and Correlates of Protection for Next Generation Influenza Vaccines

italy siena

 

31 March - 2 April 2019

 

                                                              

 OVERVIEW

As next generation influenza vaccine technologies are developed and undergo clinical evaluation, new immunological assays and immune correlates of protection will be needed to estimate the immunogenicity and protective efficacy of these vaccines. This conference aims to bring together scientists from academia, industry, and government public health, standardisation and regulatory agencies that develop and evaluate seasonal and pandemic influenza vaccines with the following objectives:

  • to identify the most relevant immunological assays needed for evaluation of next-generation influenza vaccines
  • to discuss the path forward for development, harmonization and standardization of new assays
  • to develop strategies to investigate the immune correlates of protection for next-generation vaccines

The meeting will be attended by key opinion leaders and decision makers in influenza research/policy.

ISIRV LTD - Registered Address: Office 7, 35-37 Ludgate Hill, London EC4M  7JN United Kingdom | Registered Company Number: 6021083 (England & Wales) | Registered Charity Number: 1118829